Applaggin
Latest Information Update: 07 Mar 2007
At a glance
- Originator Biogen
- Class Anti-ischaemics; Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemic heart disorders; Thrombosis
Most Recent Events
- 17 Nov 2003 Biogen has merged with IDEC Pharmaceuticals to form Biogen Idec